DK1034007T3 - Fremgangsmåde til fremstilling af en enkeltdosisspröjte omfattende en frysetörret proteinsammensætning til indgivelse af et volumen mindre end 0,5 ml - Google Patents

Fremgangsmåde til fremstilling af en enkeltdosisspröjte omfattende en frysetörret proteinsammensætning til indgivelse af et volumen mindre end 0,5 ml

Info

Publication number
DK1034007T3
DK1034007T3 DK98957272T DK98957272T DK1034007T3 DK 1034007 T3 DK1034007 T3 DK 1034007T3 DK 98957272 T DK98957272 T DK 98957272T DK 98957272 T DK98957272 T DK 98957272T DK 1034007 T3 DK1034007 T3 DK 1034007T3
Authority
DK
Denmark
Prior art keywords
less
volume
freeze
administration
preparing
Prior art date
Application number
DK98957272T
Other languages
English (en)
Inventor
Ebba Florin-Robertsson
Elvy Hoekby
Karin Limrell
Ulf Nilsson
Anders Stroem
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Application granted granted Critical
Publication of DK1034007T3 publication Critical patent/DK1034007T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98957272T 1997-11-28 1998-11-19 Fremgangsmåde til fremstilling af en enkeltdosisspröjte omfattende en frysetörret proteinsammensætning til indgivelse af et volumen mindre end 0,5 ml DK1034007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704405A SE9704405D0 (sv) 1997-11-28 1997-11-28 New syringe
PCT/SE1998/002096 WO1999027983A1 (en) 1997-11-28 1998-11-19 A ONE DOSE SYRINGE, COMPRISING A FREEZE-DRIED PROTEIN COMPOSITION, FOR ADMINISTERING OF A VOLUME LESS THAN 0.5 ml

Publications (1)

Publication Number Publication Date
DK1034007T3 true DK1034007T3 (da) 2007-05-21

Family

ID=20409182

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957272T DK1034007T3 (da) 1997-11-28 1998-11-19 Fremgangsmåde til fremstilling af en enkeltdosisspröjte omfattende en frysetörret proteinsammensætning til indgivelse af et volumen mindre end 0,5 ml

Country Status (24)

Country Link
US (1) US6152897A (da)
EP (1) EP1034007B1 (da)
JP (1) JP4564652B2 (da)
KR (1) KR100567358B1 (da)
CN (1) CN1156315C (da)
AT (1) ATE354390T1 (da)
AU (1) AU742494B2 (da)
CA (1) CA2311754C (da)
CY (1) CY1106403T1 (da)
CZ (1) CZ300255B6 (da)
DE (1) DE69837159T2 (da)
DK (1) DK1034007T3 (da)
ES (1) ES2281142T3 (da)
HK (1) HK1032920A1 (da)
HU (1) HUP0004410A3 (da)
MX (1) MXPA00005214A (da)
NO (1) NO324692B1 (da)
NZ (1) NZ505150A (da)
PL (1) PL193243B1 (da)
PT (1) PT1034007E (da)
RU (1) RU2214285C2 (da)
SE (1) SE9704405D0 (da)
SK (1) SK285668B6 (da)
WO (1) WO1999027983A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7959600B2 (en) * 2004-12-30 2011-06-14 Byeong S. Chang Container closure delivery system
US20060144869A1 (en) * 2004-12-30 2006-07-06 Chang Byeong S Container closure delivery system
US20060157507A1 (en) * 2004-12-30 2006-07-20 Chang Byeong S Multi-functional container closure delivery system
US8062254B2 (en) 2008-01-08 2011-11-22 MacLean, LLC Spring driven adjustable oral syringe
EP2663275B1 (en) 2011-01-10 2017-03-08 Byeong Seon Chang Compact medication reconstitution device and method
GB2498774A (en) 2012-01-27 2013-07-31 Bruce Roser Glass-stabilised biological materials and syringe
CA2925416A1 (en) 2013-09-27 2015-04-02 Hanmi Pharm. Co., Ltd. Sustained type human growth hormone preparation
MX2017003095A (es) 2014-09-09 2018-01-26 Seon Chang Byeong Dispositivo y método de entrega de solución.
EP3549946A4 (en) * 2016-11-29 2020-10-21 Spiber Inc. COMPOSITION OF PROTEIN, ITS PRODUCTION PROCESS AND PROCESS FOR IMPROVING THERMAL STABILITY
CN108498467B (zh) * 2018-05-21 2019-03-05 中山未名海济生物医药有限公司 注射用重组人生长激素无菌粉末及其制备方法
IL272145A (en) * 2020-01-20 2021-07-29 Stem Cell Medicine Ltd Cosmetic preparations with protein concentrate from a conditioned growth medium of stem cells from adipose tissue

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86799A (en) * 1987-07-02 1993-03-15 Kabi Pharmacia Ab Method and device for injection
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
JP3108077B2 (ja) * 1989-06-08 2000-11-13 住友製薬株式会社 製剤投与器
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5158546A (en) * 1991-08-07 1992-10-27 Habley Medical Technology Corp. Controlled action self-mixing vial
US5281198A (en) * 1992-05-04 1994-01-25 Habley Medical Technology Corporation Pharmaceutical component-mixing delivery assembly
SE9202108D0 (sv) * 1992-07-07 1992-07-07 Kabi Pharmacia Ab Dual-chamber injection cartridge
MD1699F2 (ro) * 1992-07-31 2001-07-31 Genentech, Inc. Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei
US5334162A (en) * 1993-03-15 1994-08-02 Eli Lilly And Company Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same
FR2752733B1 (fr) * 1996-09-05 1998-11-06 Inst Nat Sante Rech Med Dispositif permeable a base d'hydrogel contenant des cellules vivantes, et ses applications

Also Published As

Publication number Publication date
AU742494B2 (en) 2002-01-03
WO1999027983A1 (en) 1999-06-10
CZ300255B6 (cs) 2009-04-01
KR20010032514A (ko) 2001-04-25
SE9704405D0 (sv) 1997-11-28
HUP0004410A3 (en) 2003-05-28
NO324692B1 (no) 2007-12-03
CA2311754A1 (en) 1999-06-10
DE69837159D1 (de) 2007-04-05
AU1356699A (en) 1999-06-16
EP1034007B1 (en) 2007-02-21
CA2311754C (en) 2007-12-18
CY1106403T1 (el) 2011-10-12
NO20002754L (no) 2000-05-29
KR100567358B1 (ko) 2006-04-04
CN1156315C (zh) 2004-07-07
CN1280511A (zh) 2001-01-17
EP1034007A1 (en) 2000-09-13
DE69837159T2 (de) 2007-11-22
ATE354390T1 (de) 2007-03-15
PL193243B1 (pl) 2007-01-31
CZ20001948A3 (cs) 2001-04-11
US6152897A (en) 2000-11-28
MXPA00005214A (es) 2002-04-24
PT1034007E (pt) 2007-04-30
NO20002754D0 (no) 2000-05-29
SK285668B6 (sk) 2007-06-07
RU2214285C2 (ru) 2003-10-20
JP2001524360A (ja) 2001-12-04
ES2281142T3 (es) 2007-09-16
JP4564652B2 (ja) 2010-10-20
PL340731A1 (en) 2001-02-26
HUP0004410A2 (hu) 2001-04-28
HK1032920A1 (en) 2001-08-10
SK7202000A3 (en) 2001-05-10
NZ505150A (en) 2002-08-28

Similar Documents

Publication Publication Date Title
CY1106403T1 (el) Μεθοδος για την παραγωγη μιας συριγγας μιας δοσης, που πepιλαμβανει μια ξηρανθεισα μεσω ψυξης συνθεση πρωτεϊνης, για τη χορηγηση ενος ογκου λιγοτepου απο 0,5 ml
CA1329543C (en) Human growth hormone formulation
EA200700389A1 (ru) Стабильный при хранении инфузионный раствор дигидроптеридинонов
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
KR960009929B1 (ko) 안정화된 에리트로포이에틴제제
HRP20050639A2 (en) Novel dry powder inhalation system for transpulmonary administration
BR9714015A (pt) Formulações farmacêuticas para distribuição de droga prolongada
ATE205090T1 (de) Eine glucagon enthaltende pharmazeutische zubereitung
EP1044015A4 (en) FORMULATION FOR AMYLIN PEPTIDAGONISTS
CO5050325A1 (es) Composiciones que contienen acidos difosfonicos
KR19990064322A (ko) 부갑상선 호르몬을 함유하는 안정한 약제학적 투여 제제
JPS54147916A (en) Preparation of urokinase injection
AR017973A1 (es) Formulacion farmaceutica isotonica, uso de dicha formulacion en la preparacion de un medicamento para uso en la terapia de una enfermedad autoinmune,y metodo para mejorar el almacenamiento de un anticuerpo
KR900015749A (ko) 인터루킨-1제형
RU2000116647A (ru) Однодозовый шприц, содержащий композицию лиофилизованного белка, для введения объема менее, чем 0,5 мл
DE58906232D1 (de) Azelastin enthaltende Arzneimittel mit kontrollierter Wirkstoffabgabe.
US5114931A (en) Injectable therapeutic compositions containing stable s-adenosyl-l-methionine salts
JP2708749B2 (ja) 修飾型ｔＰＡ含有注射用組成物
ES2167189A1 (es) Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
Sundell et al. Structure and Function of the Dog Gastric Mucosa During and After a 1–Year Treatment with Omeprazole. II. Effects on Gastric Acid Secretion and Blood Levels of Gastric Hormones
EP0063328A2 (en) Compositions containing secretin and method for preventing the adsorption of secretin
JPS63225320A (ja) 抗体を含有する安定水性組成物
CA2374933A1 (en) Grf-containing lyophilized pharmaceutical compositions
SU1702412A1 (ru) Способ моделировани недостаточности трипсина IN VIVo
JPS56138115A (en) Suppository containing acidic amino acid or derivative thereof